# A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

> **NCT04978727** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Children's Oncology Group** · enrollment: 35 (estimated)

## Conditions studied

- Medulloblastoma
- Glioblastoma Multiforme
- Anaplastic Astrocytoma
- High-grade Astrocytoma NOS
- Anaplastic Oligodendroglioma
- Anaplastic Ependymoma
- Ependymoma
- Diffuse Intrinsic Pontine Glioma

## Interventions

- **BIOLOGICAL:** SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years
- **BIOLOGICAL:** SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years
- **BIOLOGICAL:** SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years

## Key facts

- **NCT ID:** NCT04978727
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2027-04-30
- **Final completion:** 2030-02-28
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04978727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04978727, "A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04978727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*